Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail)

v3.19.1
Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail)
 3 Months Ended
Mar. 31, 2019
USD ($)
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 0
Helocyte Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 20, 2015
Avenue Therapeutics, Inc. [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 0 [1]
Annual Consulting Fee Payable Effective Date Feb. 17, 2015 [1]
Mustang Bio, Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 13, 2015
Checkpoint Therapeutics, Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 17, 2015
Cellvation Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Oct. 31, 2016
Caelum Bio sciences Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 0 [2]
Annual Consulting Fee Payable Effective Date Jan. 01, 2017 [2]
Cyprium Bio sciences Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 13, 2017
Aevitas Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Jul. 28, 2017
Tamid Bio sciences Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Nov. 30, 2017
Fortress Biotech Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ (3,500)
[1] Concurrently with the execution and delivery of the SPMA entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).
[2] Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of a Development Option and Share Purchase Agreement (“DOSPA”) between Caelum and Alexion Therapeutics, Inc. (See Note 4).